UroGen Pharma (URGN) stock falls as the company faces a major setback after an FDA panel votes against its bladder cancer ...

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease ...

The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with ...

Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...

Roger Li, MD, discusses the MoonRISe-1 study evaluating TAR-210 in FGFR-altered intermediate-risk non-muscle-invasive bladder cancer.

ImmunityBio (NASDAQ: IBRX) gains momentum as Piper Sandler upgrades to Overweight on Anktiva's success and strong growth ...

UroGen Pharma (NASDAQ: URGN) shares plummeted 29% following concerns from FDA staff regarding the efficacy of its bladder ...

UroGen Pharma shares fell to a 52-week low after a Food and Drug Administration document indicated disagreements with the company about certain aspects of studies of bladder cancer drug UGN-102. The ...

Detailed price information for Aura Biosciences Inc (AURA-Q) from The Globe and Mail including charting and trades.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of ...

On Monday, Mad Money host Jim Cramer addressed the market’s reaction to the recent U.S. debt downgrade by Moody’s.